Stay updated with breaking news from Heather Wakelee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Giving a glimpse into significant data and highlighting the importance of balancing toxicities with efficacy as the non–small cell lung cancer treatment paradigm shifts.
Heather Wakelee, MD, FASCO, discusses the significance of early data on the use of taletrectinib in patients with ROS1-positive non–small cell lung cancer from the phase 2 TRUST-II trial.
The 2023 ESMO Congress, which is taking place in Madrid, Spain, and will continue to be accessible online via a virtual platform, is gearing up to kick off, and the oncology community is ready to learn more about the latest data across malignancies.
Approval marks the sixth NSCLC indication for KEYTRUDA and builds upon Merck’s progress in earlier stages of certain cancers across our oncology portfolioRAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Admi...
Keytruda plus chemotherapy is approved for resectable NSCLC as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment.